Skip to content
WorldBrand.AI

Prosensa controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2014

    Shareholder class-action allegations concerning the IPO

    An American shareholder filed a proposed class action in New York alleging that Prosensa had misled investors during its 2013 Nasdaq IPO about the prospects, expected timing, and potential economic returns of its Duchenne muscular dystrophy drug program. The available material records the allegations but does not establish a final judgment or settlement.

    Source